The Italian LGMD registry: Relative frequency, clinical features, and differential diagnosis
- Creators
- Magri, Francesca
- Nigro, Vincenzo
- Angelini, Corrado
- Mongini, Tiziana
- Mora, Marina
- Moroni, Isabella
- Toscano, Antonio
- D'Angelo, Maria Grazia
- Tomelleri, Giuliano
- Siciliano, Gabriele
- Ricci, Giulia
- BRUNO, CLAUDIO
- Corti, Stefania
- Musumeci, Olimpia
- Tasca, Giorgio
- Ricci, Enzo
- Monforte, Mauro
- Sciacco, Monica
- FIORILLO, CHIARA
- Gandossini, Sandra
- MINETTI, CARLO
- Morandi, Lucia
- Savarese, Marco
- Di Fruscio, Giuseppina
- Semplicini, Claudio
- Pegoraro, Elena
- Govoni, Alessandra
- Brusa, Roberta
- Del Bo, Roberto
- Ronchi, Dario
- Moggio, Maurizio
- Bresolin, Nereo
- Comi, Giacomo Pietro
- Others:
- Magri, Francesca
- Nigro, Vincenzo
- Angelini, Corrado
- Mongini, Tiziana
- Mora, Marina
- Moroni, Isabella
- Toscano, Antonio
- D'Angelo, Maria Grazia
- Tomelleri, Giuliano
- Siciliano, Gabriele
- Ricci, Giulia
- Bruno, Claudio
- Corti, Stefania
- Musumeci, Olimpia
- Tasca, Giorgio
- Ricci, Enzo
- Monforte, Mauro
- Sciacco, Monica
- Fiorillo, Chiara
- Gandossini, Sandra
- Minetti, Carlo
- Morandi, Lucia
- Savarese, Marco
- Di Fruscio, Giuseppina
- Semplicini, Claudio
- Pegoraro, Elena
- Govoni, Alessandra
- Brusa, Roberta
- Del Bo, Roberto
- Ronchi, Dario
- Moggio, Maurizio
- Bresolin, Nereo
- Comi, Giacomo Pietro
Description
Introduction Limb girdle muscular dystrophies (LGMDs) are characterized by high molecular heterogeneity, clinical overlap, and a paucity of specific biomarkers. However, their molecular definition is fundamental for prognostic and therapeutic purposes. Methods We created an Italian LGMD registry that included 370 molecularly defined patients. We reviewed detailed retrospective and prospective data and compared each LGMD subtype for differential diagnosis purposes. Results LGMD2A and 2B are the most frequent forms in Italy. The ages at disease onset, clinical progression, and cardiac and respiratory involvement can vary greatly between each LGMD subtype. In a set of extensively studied patients, targeted next-generation sequencing (NGS) identified mutations in 36.5% of cases.
Additional details
- URL
- http://hdl.handle.net/11567/841165
- URN
- urn:oai:iris.unige.it:11567/841165
- Origin repository
- UNIGE